Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 2970 | 2159 | 45.9 | 90% |
Classes in level above (level 3) |
Classes in level below (level 1) |
| ID, lev. below | Publications | Label for level below |
|---|---|---|
| 5224 | 1586 | ALPHAVBETA3 INTEGRIN//CILENGITIDE//ALPHAVBETA3 |
| 22326 | 329 | DISCOIDIN DOMAIN RECEPTOR//DISCOIDIN DOMAIN RECEPTOR 2//DISCOIDIN DOMAIN RECEPTORS |
| 28208 | 173 | NEPHRONECTIN//VLA 1//ALPHA 8 INTEGRIN |
| 34453 | 71 | ISTHMIN//METEORIN//NEURENSIN 2 |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ALPHAVBETA3 INTEGRIN | Author keyword | 74 | 42% | 6% | 137 |
| 2 | CILENGITIDE | Author keyword | 73 | 80% | 2% | 45 |
| 3 | DISCOIDIN DOMAIN RECEPTOR | Author keyword | 47 | 84% | 1% | 26 |
| 4 | DISCOIDIN DOMAIN RECEPTOR 2 | Author keyword | 35 | 86% | 1% | 18 |
| 5 | ALPHAVBETA3 | Author keyword | 30 | 40% | 3% | 58 |
| 6 | MED ISOTOPES | Address | 24 | 44% | 2% | 40 |
| 7 | DISCOIDIN DOMAIN RECEPTORS | Author keyword | 23 | 100% | 0% | 10 |
| 8 | DDR2 | Author keyword | 23 | 62% | 1% | 24 |
| 9 | INTETUMUMAB | Author keyword | 21 | 90% | 0% | 9 |
| 10 | DDR1 | Author keyword | 18 | 58% | 1% | 21 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ALPHAVBETA3 INTEGRIN | 74 | 42% | 6% | 137 | Search ALPHAVBETA3+INTEGRIN | Search ALPHAVBETA3+INTEGRIN |
| 2 | CILENGITIDE | 73 | 80% | 2% | 45 | Search CILENGITIDE | Search CILENGITIDE |
| 3 | DISCOIDIN DOMAIN RECEPTOR | 47 | 84% | 1% | 26 | Search DISCOIDIN+DOMAIN+RECEPTOR | Search DISCOIDIN+DOMAIN+RECEPTOR |
| 4 | DISCOIDIN DOMAIN RECEPTOR 2 | 35 | 86% | 1% | 18 | Search DISCOIDIN+DOMAIN+RECEPTOR+2 | Search DISCOIDIN+DOMAIN+RECEPTOR+2 |
| 5 | ALPHAVBETA3 | 30 | 40% | 3% | 58 | Search ALPHAVBETA3 | Search ALPHAVBETA3 |
| 6 | DISCOIDIN DOMAIN RECEPTORS | 23 | 100% | 0% | 10 | Search DISCOIDIN+DOMAIN+RECEPTORS | Search DISCOIDIN+DOMAIN+RECEPTORS |
| 7 | DDR2 | 23 | 62% | 1% | 24 | Search DDR2 | Search DDR2 |
| 8 | INTETUMUMAB | 21 | 90% | 0% | 9 | Search INTETUMUMAB | Search INTETUMUMAB |
| 9 | DDR1 | 18 | 58% | 1% | 21 | Search DDR1 | Search DDR1 |
| 10 | RGD | 14 | 14% | 4% | 90 | Search RGD | Search RGD |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ALPHAVBETA3 | 140 | 32% | 17% | 365 |
| 2 | ALPHAVBETA3 INTEGRIN | 82 | 21% | 16% | 342 |
| 3 | CANCER ALPHAV INTEGRIN EXPRESSION | 79 | 85% | 2% | 41 |
| 4 | INTEGRIN ALPHAVBETA3 EXPRESSION | 61 | 58% | 3% | 71 |
| 5 | DDR1 | 48 | 91% | 1% | 20 |
| 6 | F 18 GALACTO RGD | 47 | 88% | 1% | 22 |
| 7 | GLIOMA INTEGRIN ALPHAVBETA3 EXPRESSION | 44 | 88% | 1% | 21 |
| 8 | TYROSINE KINASE DDR1 | 38 | 93% | 1% | 14 |
| 9 | ALPHAVBETA3 ANTAGONISTS | 37 | 75% | 1% | 27 |
| 10 | ALPHA V BETA 3 EXPRESSION | 32 | 85% | 1% | 17 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Integrins in cancer: biological implications and therapeutic opportunities | 2010 | 811 | 187 | 45% |
| RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis | 2012 | 115 | 95 | 49% |
| Discoidin Domain Receptor Functions in Physiological and Pathological Conditions | 2014 | 10 | 171 | 81% |
| Ligands for Mapping alpha(v)beta(3)-Integrin Expression in Vivo | 2009 | 138 | 73 | 77% |
| Radiolabeled Cyclic RGD Peptides as Integrin alpha(v)beta(3)-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency | 2009 | 145 | 120 | 72% |
| Radiolabelled RGD peptides for imaging and therapy | 2012 | 53 | 71 | 76% |
| Integrins as therapeutic targets | 2012 | 87 | 57 | 47% |
| Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated Signaling | 2013 | 29 | 88 | 63% |
| Discoidin domain receptor tyrosine kinases: new players in cancer progression | 2012 | 48 | 178 | 74% |
| Integrins in angiogenesis and lymphangiogenesis | 2008 | 358 | 139 | 34% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MED ISOTOPES | 24 | 44% | 1.9% | 40 |
| 2 | INTERDIPARTIMENTALE STUDI BIOMOL PLICAZ I | 8 | 100% | 0.2% | 5 |
| 3 | ONCOL PLATFORM | 6 | 100% | 0.2% | 4 |
| 4 | RADIOL MIPS | 6 | 100% | 0.2% | 4 |
| 5 | MOL IMAGING NANOMED | 5 | 18% | 1.1% | 24 |
| 6 | INTER PRECLIN DEV MOL IMAGING CISPIM | 4 | 67% | 0.2% | 4 |
| 7 | RADIOL BIOX | 4 | 67% | 0.2% | 4 |
| 8 | ADHES ANGIOGENESIS GRP | 4 | 75% | 0.1% | 3 |
| 9 | EUGENE MARCIA PELBAUM INVAS MOL THER E | 3 | 100% | 0.1% | 3 |
| 10 | BONE BIOL OSTEOPOROSIS | 3 | 19% | 0.7% | 15 |
Related classes at same level (level 2) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000034026 | FOCAL ADHESION KINASE//INTEGRIN LINKED KINASE//FAK |
| 2 | 0.0000025427 | LAMININ//FIBRONECTIN//INVASION & METASTASIS |
| 3 | 0.0000023462 | GALLIUM NITRATE//GE 68 GA 68 GENERATOR//GALLIUM 68 |
| 4 | 0.0000017207 | LYMPHANGIOGENESIS//ANGIOGENESIS//ENDOSTATIN |
| 5 | 0.0000017085 | E SELECTIN//SELECTIN//ICAM 1 |
| 6 | 0.0000014133 | C 11RACLOPRIDE//FLUORINE 18//C 11FLB 457 |
| 7 | 0.0000010088 | RHENIUMV//TECHNETIUM COMPLEXES//OXORHENIUMV |
| 8 | 0.0000009626 | GLASGOW PROGNOSTIC SCORE//NEUTROPHIL TO LYMPHOCYTE RATIO//NEUTROPHIL LYMPHOCYTE RATIO |
| 9 | 0.0000009383 | TIP30//LYMPHATIC SYSTEM MR//LYMPHOGRAPHY |
| 10 | 0.0000009005 | DCE MRI//CT PERFUSION//INTRAVOXEL INCOHERENT MOTION |